Structure-Activity Relationships Of Noncovalent Immunoproteasome Beta 5i-Selective Dipeptides

The immunoproteasome (i-20S) has emerged as a therapeutic target for autoimmune and inflammatory disorders and hematological malignancies. Inhibition of the chymotryptic beta 5i subunit of i-20S inhibits T cell activation, B cell proliferation, and dendritic cell differentiation in vitro and suppresses immune responses in animal models of autoimmune disorders and allograft rejection. However, cytotoxicity to immune cells has accompanied the use of covalently reactive beta 5i inhibitors, whose activity against the constitutive proteasome (c-20S) is cumulative with the time of exposure. Herein, we report a structure-activity relationship study of a class of noncovalent proteasome inhibitors with picomolar potencies and 1000-fold selectivity for i-20S over c-20S. Furthermore, these inhibitors are specific for beta 5i over the other five active subunits of i-20S and c-20S, providing useful tools to study the functions of beta 5i in immune responses. The potency of these compounds in inhibiting human T cell activation suggests that they may have therapeutic potential.